Lexicon Pharmaceuticals (LXRX) Stock Statistics & Valuation Metrics

Lexicon Pharmaceuticals has a market cap or net worth of $184.29M. The enterprise value is $135.08M.

Lexicon Pharmaceuticals has 361,492,300 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lexicon Pharmaceuticals’s return on equity (ROE) is -1.37 and return on invested capital (ROIC) is -77.50%.

The current PE Ratio of Lexicon Pharmaceuticals is -1.18. Lexicon Pharmaceuticals’s PEG ratio is 0.06.

In the last 12 months, Lexicon Pharmaceuticals had revenue of 31.08M and earned -200.40M in profits. Earnings per share was -0.63.

In the last 12 months, operating cash flow was -178.78M and capital expenditures -1.03M, giving a free cash flow of -179.81M billion.

Lexicon Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Lexicon Pharmaceuticals upcoming earnings date is May 1, 2025, TBA Not Confirmed.

Lexicon Pharmaceuticals as a current ratio of 5.44, with Debt / Equity ratio of 74.27%

In the past 12 months, Lexicon Pharmaceuticals has paid 0.00 in taxes.

Lexicon Pharmaceuticals EV to EBITDA ratio is -1.51, with an EV/FCF ratio of -1.55.

Lexicon Pharmaceuticals has $237.96M in cash and marketable securities with $64.80M in debt, giving a net cash position of -$129.56M billion.

Gross margin is 97.55%, with operating margin of -634.20%, and net profit margin of -644.78%.

The average price target for Lexicon Pharmaceuticals is $5.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy